U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Substance Class Protein
Created
by admin
on Tue Apr 01 17:04:18 GMT 2025
Edited
by admin
on Tue Apr 01 17:04:18 GMT 2025
Protein Sub Type
Sequence Type COMPLETE
Record UNII
Z3LSI83ND8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
5-HT-6
Preferred Name English
5-HYDROXYTRYPTAMINE RECEPTOR 6
Common Name English
5-HT6
Common Name English
SEROTONIN RECEPTOR 6
Common Name English
HTR6
Common Name English
Code System Code Type Description
FDA UNII
Z3LSI83ND8
Created by admin on Tue Apr 01 17:04:19 GMT 2025 , Edited by admin on Tue Apr 01 17:04:19 GMT 2025
PRIMARY
UNIPROT
P50406
Created by admin on Tue Apr 01 17:04:19 GMT 2025 , Edited by admin on Tue Apr 01 17:04:19 GMT 2025
PRIMARY
From To
1_99 1_180
Related Record Type Details
Structure of EMD-386088
PARTIAL AGONIST->TARGET
Structure of SB-773812
INHIBITOR -> TARGET
Structure of SERTINDOLE
INHIBITOR -> TARGET
Structure of CERLAPIRDINE
ANTAGONIST->TARGET
Structure of PF-05212377
INHIBITOR -> TARGET
Full antagonist SAM-760 completed phase I trials with no adverse effects at doses of up to 50 mg daily. Pfizer terminated a phase II trial after SAM-760 30 mg/day failed to produce an improvement in cognition in patients already taking a stable dose of donepezil.
Structure of AVN-211
INHIBITOR -> TARGET
ANTAGONIST
Structure of SB-271046
INHIBITOR -> TARGET
Structure of MASUPIRDINE
INHIBITOR -> TARGET
Structure of PALIPERIDONE
INHIBITOR -> TARGET
INHIBITOR
Ki
Structure of IDALOPIRDINE
INHIBITOR -> TARGET
Phase III trials showed weak efficacy as compared to phase II trials, which may be explained by underdosing. Phase II trials evaluated the use of 90 mg daily (30 mg TID) as an adjunct to an acetylcholinesterase inhibitor. Study investigators decided to lower the dose of idalopirdine in phase III trials based on receptor occupancy analysis conducted by PET scan
Structure of SB-399885
INHIBITOR -> TARGET
ANTAGONIST
Structure of BENZENESULFONIC ACID, 2,6-DIFLUORO-, 1-METHYL-3-(1-METHYL-4-PIPERIDINYL)-1H-INDOL-5-YL ESTER
INHIBITOR -> TARGET
Structure of 6-FLUORO-DMT
AGONIST -> TARGET
Structure of LATREPIRDINE
INHIBITOR -> TARGET
Ki
Structure of LANDIPIRDINE
INHIBITOR -> TARGET
Structure of Maritupirdine
INHIBITOR -> TARGET
Structure of INTEPIRDINE
INHIBITOR -> TARGET
Structure of ARIPIPRAZOLE
LIGAND->TARGET
Ki
Structure of ST-1936
AGONIST -> TARGET
Structure of RISPERIDONE
WEAK INHIBITOR->TARGET
INHIBITOR
Ki
Structure of LYSERGIDE
AGONIST -> TARGET
Ki
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966